A Phase 1 interventional study of Radiprodil in Hepatic Impairment, sponsored by GRIN Therapeutics, Inc.. Recruiting at 2 sites in United States. Open to participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-05-08.
Sponsored by GRIN Therapeutics, Inc. · Phase 1, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This Phase 1, open-label study will evaluate the pharmacokinetics (PK), safety, and tolerability of a single oral dose of radiprodil in adults with varying degrees of hepatic impairment compared with healthy participants. Radiprodil is being developed as a potential treatment for GRIN-related neurodevelopmental disorders, tuberous sclerosis complex, and focal cortical dysplasia.
Approximately 40 adults aged 18 to 75 years will be enrolled into five cohorts based on liver function (mild, moderate, or severe hepatic impairment) or healthy status. Participants will receive a single 15 mg oral dose of radiprodil and remain in the clinical research unit for intensive PK and safety monitoring through Day 6.
The primary objective is to characterize the PK profile of radiprodil in participants with hepatic impairment compared with healthy participants. Safety and tolerability will also be assessed. Results from this study will help determine whether dose adjustments are needed in individuals with impaired liver function.
This is a Phase 1, open-label, two-arm study designed to assess the pharmacokinetics (PK), safety, and tolerability of a single oral dose of radiprodil in adults with varying degrees of hepatic impairment compared with matched healthy participants.
Up to 40 participants aged 18 to 75 years will be enrolled across five cohorts. Participants will include individuals with mild (Child-Pugh Class A), moderate (Child-Pugh Class B), or severe (Child-Pugh Class C) hepatic impairment, as well as healthy participants matched for age, sex, and body mass index where feasible.
The study consists of a Screening Period (Days -28 to -2), check-in on Day -1, and a Treatment Period. Participants will be confined to the clinical research unit from Day -1 through completion of study assessments on Day 6. On Day 1, all participants will receive a single oral dose of radiprodil 15 mg administered as an oral suspension.
Serial blood samples will be collected to determine plasma concentrations of radiprodil and its major metabolites. Key PK parameters include area under the concentration-time curve (AUC), maximum observed concentration (Cmax), time to maximum concentration (Tmax), terminal half-life (t½), apparent clearance (CL/F), and apparent volume of distribution (Vz/F).
Safety and tolerability will be evaluated throughout the study by monitoring adverse events, vital signs, electrocardiograms, clinical laboratory tests, physical examinations, and Columbia Suicide Severity Rating Scale assessments.
Hepatic impairment can alter the metabolism and exposure of many drugs. Because radiprodil is primarily eliminated via hepatic metabolism, this study is intended to characterize the effect of liver impairment on radiprodil exposure and to inform potential dosing recommendations for future clinical use.
GRIN Therapeutics, Inc. is the lead sponsor of 7 studies on the registry; 2 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Child-Pugh class
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants with mild hepatic impairment (Child-Pugh Class A).
Drug: Radiprodil
Participants with moderate hepatic impairment (Child-Pugh Class B).
Drug: Radiprodil
Healthy participants matched to the mild and moderate hepatic impairment cohorts by age, sex, and body mass index where feasible.
Drug: Radiprodil
Participants with severe hepatic impairment (Child-Pugh Class C).
Drug: Radiprodil
Healthy participants matched to the severe hepatic impairment cohort by age, sex, and body mass index where feasible.
Drug: Radiprodil
Radiprodil will be administered as a single oral dose of 15 mg (2.0 mL of 7.5 mg/mL oral suspension) on Day 1 under fed conditions. Participants will fast overnight for at least 10 hours prior to dosing and consume a standard breakfast approximately 30 minutes before administration. Study drug will be administered with approximately 240 mL of water. All participants across cohorts will receive the same single-dose regimen.
Also known as: RGH-896, Radiprodil oral suspension
Area Under the Plasma Concentration-Time Curve from Time 0 to Time of Last Quantifiable Concentration (AUClast) of Radiprodil
Plasma AUClast of radiprodil following a single oral dose in participants with varying degrees of hepatic impairment and healthy participants.
Time frame: Day 1 (pre-dose) through Day 6 (120 hours post-dose)
Area Under the Plasma Concentration-Time Curve from Time 0 Extrapolated to Infinity (AUCinf) of Radiprodil
Plasma AUCinf of radiprodil following a single oral dose in participants with varying degrees of hepatic impairment and healthy participants.
Time frame: Day 1 (pre-dose) through Day 6 (120 hours post-dose)
Maximum Observed Plasma Concentration (Cmax) of Radiprodil
Plasma Cmax of radiprodil following a single oral dose in participants with varying degrees of hepatic impairment and healthy participants.
Time frame: Day 1 (pre-dose) through Day 6 (120 hours post-dose)
Time to Maximum Observed Plasma Concentration (Tmax) of Radiprodil
Plasma Tmax of radiprodil following a single oral dose in participants with varying degrees of hepatic impairment and healthy participants.
Time frame: Day 1 (pre-dose) through Day 6 (120 hours post-dose)
Time Before First Quantifiable Plasma Concentration (Tlag) of Radiprodil
Plasma Tlag of radiprodil following a single oral dose in participants with varying degrees of hepatic impairment and healthy participants.
Time frame: Day 1 (pre-dose) through Day 6 (120 hours post-dose)
Apparent Total Body Clearance (CL/F) of Radiprodil
Apparent total body clearance of radiprodil following a single oral dose in participants with varying degrees of hepatic impairment and healthy participants.
Time frame: Day 1 (pre-dose) through Day 6 (120 hours post-dose)
Apparent Volume of Distribution Based on the Terminal Phase (Vz/F) of Radiprodil
Apparent volume of distribution of radiprodil following a single oral dose in participants with varying degrees of hepatic impairment and healthy participants.
Time frame: Day 1 (pre-dose) through Day 6 (120 hours post-dose)
Terminal Elimination Half-Life (t½) of Radiprodil
Plasma terminal elimination half-life of radiprodil following a single oral dose in participants with varying degrees of hepatic impairment and healthy participants.
Time frame: Day 1 (pre-dose) through Day 6 (120 hours post-dose)
Area Under the Plasma Concentration-Time Curve from Time 0 to Time of Last Quantifiable Concentration (AUClast) of FBPO
Plasma AUClast of the radiprodil major metabolite FBPO following a single oral dose in participants with varying degrees of hepatic impairment and healthy participants
Time frame: Day 1 (pre-dose) through Day 6 (120 hours post-dose)
Area Under the Plasma Concentration-Time Curve from Time 0 Extrapolated to Infinity (AUCinf) of FBPO
Plasma AUCinf of FBPO following a single oral dose in participants with varying degrees of hepatic impairment and healthy participants.
Time frame: Day 1 (pre-dose) through Day 6 (120 hours post-dose)
Maximum Observed Plasma Concentration (Cmax) of FBPO
Plasma Cmax of FBPO following a single oral dose in participants with varying degrees of hepatic impairment and healthy participants.
Time frame: Day 1 (pre-dose) through Day 6 (120 hours post-dose)
Time to Maximum Observed Plasma Concentration (Tmax) of FBPO
Plasma Tmax of FBPO following a single oral dose in participants with varying degrees of hepatic impairment and healthy participants.
Time frame: Day 1 (pre-dose) through Day 6 (120 hours post-dose)
Time Before First Quantifiable Plasma Concentration (Tlag) of FBPO
Plasma Tlag of FBPO following a single oral dose in participants with varying degrees of hepatic impairment and healthy participants.
Time frame: Day 1 (pre-dose) through Day 6 (120 hours post-dose)
Terminal Elimination Half-Life (t½) of FBPO
Plasma terminal half-life of FBPO following a single oral dose in participants with varying degrees of hepatic impairment and healthy participants.
Time frame: Day 1 (pre-dose) through Day 6 (120 hours post-dose)
Area Under the Plasma Concentration-Time Curve from Time 0 to Time of Last Quantifiable Concentration (AUClast) of ORR-S
Plasma AUClast of the radiprodil major metabolite ORR-S following a single oral dose in participants with varying degrees of hepatic impairment and healthy participants.
Time frame: Day 1 (pre-dose) through Day 6 (120 hours post-dose)
Area Under the Plasma Concentration-Time Curve from Time 0 Extrapolated to Infinity (AUCinf) of ORR-S
Plasma AUCinf of ORR-S following a single oral dose in participants with varying degrees of hepatic impairment and healthy participants.
Time frame: Day 1 (pre-dose) through Day 6 (120 hours post-dose)
Maximum Observed Plasma Concentration (Cmax) of ORR-S
Plasma Cmax of ORR-S following a single oral dose in participants with varying degrees of hepatic impairment and healthy participants.
Time frame: Day 1 (pre-dose) through Day 6 (120 hours post-dose)
Time to Maximum Observed Plasma Concentration (Tmax) of ORR-S
Plasma Tmax of ORR-S following a single oral dose in participants with varying degrees of hepatic impairment and healthy participants.
Time frame: Day 1 (pre-dose) through Day 6 (120 hours post-dose)
Time Before First Quantifiable Plasma Concentration (Tlag) of ORR-S
Plasma Tlag of ORR-S following a single oral dose in participants with varying degrees of hepatic impairment and healthy participants.
Time frame: Day 1 (pre-dose) through Day 6 (120 hours post-dose)
Terminal Elimination Half-Life (t½) of ORR-S
Plasma terminal half-life of ORR-S following a single oral dose in participants with varying degrees of hepatic impairment and healthy participants.
Time frame: Day 1 (pre-dose) through Day 6 (120 hours post-dose)
Number of Participants With Treatment-Emergent Adverse Events (TEAEs)
Incidence of treatment-emergent adverse events following a single oral dose of radiprodil, summarized by system organ class and preferred term.
Time frame: Day 1 through Day 6 (120 hours post-dose)
Number of Participants With Serious Adverse Events (SAEs)
Incidence of serious adverse events following a single oral dose of radiprodil.
Time frame: Day 1 through Day 6 (120 hours post-dose)
Number of Participants With Adverse Events Leading to Discontinuation
Incidence of participants who discontinue the study due to an adverse event following a single oral dose of radiprodil.
Time frame: Day 1 through Day 6 (120 hours post-dose)
Change From Baseline in Systolic Blood Pressure (mmHg)
Change from baseline in systolic blood pressure following a single oral dose of radiprodil.
Time frame: Baseline (Day -1) through Day 6 (120 hours post-dose)
Change From Baseline in Diastolic Blood Pressure (mmHg)
Change from baseline in diastolic blood pressure following a single oral dose of radiprodil.
Time frame: Baseline (Day -1) through Day 6 (120 hours post-dose)
Change From Baseline in Heart Rate (beats per minute)
Change from baseline in heart rate following a single oral dose of radiprodil.
Time frame: Baseline (Day -1) through Day 6 (120 hours post-dose)
Change From Baseline in Respiratory Rate (breaths per minute)
Change from baseline in respiratory rate following a single oral dose of radiprodil.
Time frame: Baseline (Day -1) through Day 6 (120 hours post-dose)
Change From Baseline in Body Temperature (°C)
Change from baseline in body temperature following a single oral dose of radiprodil.
Time frame: Baseline (Day -1) through Day 6 (120 hours post-dose)
Change From Baseline in QT Interval Corrected Using Fridericia's Formula (QTcF) (milliseconds)
Change from baseline in QT interval corrected using Fridericia's formula (QTcF) following a single oral dose of radiprodil.
Time frame: Baseline (Day -1) through Day 6 (120 hours post-dose)
Number of Participants With Clinically Significant Laboratory Abnormalities
Incidence of participants with laboratory values meeting predefined criteria for clinical significance across hematology, serum chemistry, coagulation, and urinalysis following a single oral dose of radiprodil.
Time frame: Baseline (Day -1) through Day 6 (120 hours post-dose)
Change From Baseline in Columbia-Suicide Severity Rating Scale (C-SSRS) Score
Change from baseline in Columbia-Suicide Severity Rating Scale (C-SSRS) score following a single oral dose of radiprodil.
Time frame: Baseline (Day -1) through Day 6 (120 hours post-dose)
Plan to share: No
No publications or documents are linked to this record.
Started Mar 2026 (actual). Primary completion is estimated for May 2027, 14 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Radiprodil
GRIN Therapeutics, Inc.